Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway

• Unité de recherche: INNOSUISSE
• Numéro de projet: 17517.2 PFLS-LS
• Titre du projet anglais: Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway: MIP: Cellestia Biotech SA

Description succincte (Allemand)

Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway

Description succincte (Anglais)

Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway: MIP: Cellestia Biotech SA

Résumé des résultats (Abstract) (Allemand)

Cellestia Biotech is developing first-in class oral small molecule inhibitor of the Notch pathway with a mechanism of action completely different from current therapies(GSIs and Mabs) in development to target this pathway. |The goal of this project is:|i) To dissect the mechanism of action of the novel inhibitor of Notch at molecular level.|ii) To explore the invivo anti-tumor efficacy, with a focus on Notch driven cancers that cannot be adressed by the current therapies.|

Résumé des résultats (Abstract) (Anglais)

Cellestia Biotech is developing first-in class oral small molecule inhibitor of the Notch pathway with a mechanism of action completely different from current therapies(GSIs and Mabs) in development to target this pathway. |The goal of this project is:|i) To dissect the mechanism of action of the novel inhibitor of Notch at molecular level.|ii) To explore the invivo anti-tumor efficacy, with a focus on Notch driven cancers that cannot be adressed by the current therapies.|